Skip to main content
SpringerLink
Log in

Incidence of axillary lymph node metastases in T1a and T1b breast carcinoma

  • Original Articles
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background: We investigated the incidence of axillary lymph node metastases in patients with T1a (⩽0.5 cm) and T1b (>0.5 cm and ⩽1.0 cm) breast cancers.

Methods: The charts of 2000 patients who underwent axillary lymph node dissection for breast cancer at our institution from 1989 to 1991 were reviewed. Of these, 81 patients had T1a and 166 had T1b primary breast cancers.

Results: Among the 247 patients with T1a and T1b breast cancers, nodal metastases were present in 30 (12.1%), with a 7.4% positivity rate for patients with T1a and 14.5% positivity rate for T1b tumors. Of the 212 patients who had ⩾10 nodes dissected, 29 (13.7%) had positive nodes. Of those, 6 of 60 (10.0%) patients with T1a and 23 of 152 (15.1%) with T1b tumors had positive nodes. The presence of lymphovascular invasion (LVI) predicted a significantly higher nodal positivity rate (27.8% vs. 10.9%,p=0.05).

Conclusions: Of patients with adequately evaluated axillae, 10% with T1a and 15% with T1b cancers were found to have nodal metastases. Although LVI was significantly associated with a higher risk of lymph node metastases, we could not characterize any subgroup at acceptably low risk of nodal positivity. Until a more useful prognostic indicator is discovered, axillary dissection should continue to be part of the mainstay of management for small breast cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S. Pathologic prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years.J Clin Oncol 1989;7:1239–51.

    CAS  PubMed  Google Scholar 

  2. Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer.Cancer 1983;52:1551–7.

    CAS  PubMed  Google Scholar 

  3. Ruffin WK, Stacey-Clear A, Younger J, Hoover H. Rationale for the routine axillary dissection in carcinoma of the breast.J Am Coll Surg 1995;180:245–51.

    CAS  PubMed  Google Scholar 

  4. Hayward J, Caleffi M. The significance of local control in the primary treatment of breast cancer.Arch Surg 1987;122:1244–7.

    CAS  PubMed  Google Scholar 

  5. Langlands AO, Prescott RJ, Hamilton T. A clinical trial in the management of operable breast cancerBr J Surg 1980;67:170–4.

    CAS  PubMed  Google Scholar 

  6. White RE, Vezeridis MP, Konstadoulakis M, Cole BF, Wanebo HJ, Bland KI. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions.J Am Coll Surg 1996;183:575–82.

    CAS  PubMed  Google Scholar 

  7. Cady B, Stone MD, Wayne J. New therapeutic possibilities in primary invasive breast cancer.Ann Surg 1993;218:338–49.

    CAS  PubMed  Google Scholar 

  8. Silverstein MJ, Gierson ED, Waisman JR, Senofsky GM, Colburn WJ, Gamagami P. Axillary lymph node dissection for T1a breast carcinoma, is it indicated?Cancer 1994;73:664–7.

    CAS  PubMed  Google Scholar 

  9. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases.Cancer 1989;63:181–7.

    CAS  PubMed  Google Scholar 

  10. Veronesi U, Luini A, Galimberti V, Marchini S, Sacchini V, Rilke F. Extent of metastatic axillary involvement in 1446 cases of breast cancer.Eur J Surg Oncol 1990;16:127–33.

    CAS  PubMed  Google Scholar 

  11. Silverstein MJ, Gierson ED, Waisman JR, Colburn WJ, Gamagami P. Predicting axillary node positivity in patients with invasive carcinoma of the breast by using a combination of T category and palpability.J Am Coll Surg 1995;180:700–4.

    CAS  PubMed  Google Scholar 

  12. Nevin JE, Pinzon G, Moran TJ, Baggerly JT. Minimal breast carcinoma.Am J Surg 1980;139:357–9.

    Article  CAS  PubMed  Google Scholar 

  13. Halverson KJ, Taylor ME, Perez CA, et al. Management of the axilla in patients with breast cancers one centimeter or smaller.Am J Clin Oncol 1994;17:461–6.

    CAS  PubMed  Google Scholar 

  14. Baxter N, McCready D, Chapman JA, et al. Clinical behavior of untreated axillary nodes after local treatment for primary breast cancer.Ann Surg Oncol 1996;3:235–40.

    CAS  PubMed  Google Scholar 

  15. Kiricuta CI, Tausch J. A mathematical model of axillary lymph node involvement based on 1446 complete dissections in patients with breast carcinoma.Cancer 1992;69:2496–2501.

    CAS  PubMed  Google Scholar 

  16. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, eds. Manual for Staging of Cancer, 4th ed. Philadelphia: JB Lippincott, 1992:149–54.

    Google Scholar 

  17. Walls J, Boggis CRM, Wilson M, Asbury DL, Roberts JV, Bundred NJ, Mansel RE. Treatment of the axilla in patients with screen-detected breast cancer.Br J Surg 1993;80:436–8.

    CAS  PubMed  Google Scholar 

  18. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy.Lancet 1992;339:1–15, 71–85.

    Google Scholar 

  19. Fisher B, Montague E. Comparison of radical mastectomy with alternative treatments for primary breast cancer.Cancer 1977;39:2829–39.

    Google Scholar 

  20. Fisher B, Wolmark N, Bauer M, Redmond C, Gebhardt M. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast.Surg Gynecol Obstet 1981;152:765–72.

    CAS  PubMed  Google Scholar 

  21. Harris JR, Osteen RT. Patients with early breast cancer benefit from effective axillary treatment.Breast Cancer Res Treat 1985;5:17–21.

    CAS  PubMed  Google Scholar 

  22. Cabanes PA, Salmon RJ, Vilcoq JR, Durand JC, Fourquet A, Gautier C, Asselain B. Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer.Lancet 1992;339:1245–8.

    Article  CAS  PubMed  Google Scholar 

  23. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer.Ann Surg 1994;220:391–401.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. From Breast Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

    Elisa Rush Port MD, Patrick I. Borgen MD &  Kimberly J. Van Zee MS, MD

  2. Pathology Department, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

    Lee K. Tan MD

Authors
  1. Elisa Rush Port MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lee K. Tan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patrick I. Borgen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kimberly J. Van Zee MS, MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Port, E.R., Tan, L.K., Borgen, P.I. et al. Incidence of axillary lymph node metastases in T1a and T1b breast carcinoma. Annals of Surgical Oncology 5, 23–27 (1998). https://doi.org/10.1007/BF02303759

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02303759

Key Words

Search

Navigation